Fenofibrate Bioequivalence Study (0767-031)

• Status: Completed
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine definitive bioequivalence of the United States (U.S.) and United Kingdom (UK) formulations of fenofibrate following administration of single doses in healthy adult subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Fenofibrate

Criteria

Inclusion Criteria:

• Subject is in good health

• Subject is willing to follow all study guidelines

Exclusion Criteria:

• Subject has uncontrolled high blood pressure, impaired glucose tolerance, diabetes, or other major diseases or chronic conditions that would confound the results of the study or make participation unsafe

• Female subject is receiving oral contraceptives or hormone replacement therapy